Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Brain Lesions

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    483 result(s) found for: Brain Lesions. Displaying page 1 of 25.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-005693-31 Sponsor Protocol Number: 312021 Start Date*: 2008-03-04
    Sponsor Name:BAYER
    Full Title: Contrast-enhanced MRI examination of cerebral neoplastic enhancing lesions: comparison of diagnostic efficacy of Gd-DOTA 0.5 M and gadobutrol 1.0 M at 0.1 mmol Gd/kg body weight: Intra-individual ...
    Medical condition: patients with cerebral neoplastic lesions
    Disease: Version SOC Term Classification Code Term Level
    6.1 10006131 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013128-22 Sponsor Protocol Number: HE 42/09 Start Date*: 2010-06-29
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: Lapatinib and Whole Brain Radiotherapy for patients with brain metastases from lung and breast tumors. A phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
    Medical condition: Patients with brain metastases from lung and breast tumors
    Disease: Version SOC Term Classification Code Term Level
    12.0 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-005647-24 Sponsor Protocol Number: MIA2019/CT/258 Start Date*: 2021-05-10
    Sponsor Name:Melanoma Institute Australia
    Full Title: A phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with melanoma brain met...
    Medical condition: melanoma brain metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002328-24 Sponsor Protocol Number: BRAIN Start Date*: 2015-09-04
    Sponsor Name:UZ Brussel
    Full Title: Evaluation of 68GaNOTA-Anti-HER2 VHH1 uptake in brain metastasis of cancer patients
    Medical condition: brain metastasis lesions from potential HER2 cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002282-35 Sponsor Protocol Number: rh-NGF Start Date*: 2020-05-13
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Nerve growth factor in pediatric severe traumatic brain injury : translational and clinical studies on a candidate biomarker and therapeutic drug
    Medical condition: Persistent unresponsive wakefulness syndrome (UWS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10049615 Late effects of head trauma LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005194-32 Sponsor Protocol Number: CRANIAL Start Date*: 2013-06-28
    Sponsor Name:Institut Jules Bordet
    Full Title: A phase II trial evaluating Cabazitaxel in patients with brain metastasis secondary to breast and non-small-cell lung cancer
    Medical condition: Brain metastasis secondary to HER2-negative breast cancer and NSCLC, not previously irradiated and not requiring immediate radiation.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059282 Metastases to central nervous system PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005912-28 Sponsor Protocol Number: EGF107671 Start Date*: 2007-04-16
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: Study EGF107671 – a Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radi...
    Medical condition: Brain metastases from ErbB2-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) BE (Completed) AT (Completed) FR (Completed) GR (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024477-39 Sponsor Protocol Number: 105MS302 Start Date*: 2011-05-06
    Sponsor Name:Biogen Idec Limited
    Full Title: A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) BE (Completed) DE (Completed) ES (Completed) BG (Completed) EE (Completed) GB (Completed) GR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-001281-13 Sponsor Protocol Number: KS-2004-06-SET Start Date*: 2005-11-15
    Sponsor Name:DSC Services, s.r.o.
    Full Title: Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET Study)
    Medical condition: Clinically isolated syndrome suspected from demyelinating event (no better explanation for present symptoms)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004555-21 Sponsor Protocol Number: ARRAY-818-201 Start Date*: 2019-07-08
    Sponsor Name:Array BioPharma Inc.
    Full Title: A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
    Medical condition: BRAFV600-Mutant Melanoma Brain Metastasis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006338-32 Sponsor Protocol Number: WA21493 Start Date*: 2008-05-06
    Sponsor Name:Hoffman La Roche Ltd
    Full Title: Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do...
    Medical condition: Relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) ES (Completed) CZ (Completed) SK (Completed) DK (Completed) BE (Completed) NL (Completed) FI (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004170-25 Sponsor Protocol Number: MH-110 Start Date*: Information not available in EudraCT
    Sponsor Name:Bracco Imaging S.p.A.
    Full Title: A PHASE III, MULTI-CENTER, OPEN-LABEL STUDY TO EVALUATE SAFETY AND EFFICACY OF MULTIHANCE® AT THE DOSE OF 0.10 mmol/kg IN MAGNETIC RESONANCE IMAGING OF THE CENTRAL NERVOUS SYSTEM IN PEDIATRIC PA...
    Medical condition: imaging diagnosis of highly suspected or known brain and/or spine disease, which are known to impair the Blood Brain Barrier Function
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004301-27 Sponsor Protocol Number: NIBIT-M2 Start Date*: 2012-11-08
    Sponsor Name:FONDAZIONE NIBIT
    Full Title: A randomized, Phase III study of Fotemustine versus the Combination of Fotemustine and Ipilimumab in Patients with Metastatic Melanoma with brain metastasis
    Medical condition: Subjects (men and women) 18 years old presenting with Stage IV melanoma with presence of brain metastasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000046-19 Sponsor Protocol Number: 64616 Start Date*: 2018-11-26
    Sponsor Name:Radboud University Medical Center
    Full Title: 18F-PSMA PET/CT for visualization of glioblastoma multiforme
    Medical condition: Patients with suspected/detected GBM on T1w-Gd-MRI
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006153 Brain tumor LLT
    20.0 100000004865 10053764 Brain tumor operation LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006135-29 Sponsor Protocol Number: PH-107 Start Date*: 2012-09-03
    Sponsor Name:Bracco Imaging S.p.A.
    Full Title: PHASE IV, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, CROSSOVER STUDY TO COMPARE 0.1 mmol/kg OF PROHANCE® WITH 0.1 mmol/kg OF GADOVIST®/GADAVIST™ IN MAGNETIC RESONANCE IMAGING (MRI) OF THE BRAIN (TRUTH)
    Medical condition: Have confirmed or are highly suspected of brain disease likely to enhance as determined by the following: clinical/neurological symptomatology; diagnostic testing, such as CT or previous MRI exam...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10022891 - Investigations 10029820 Nuclear magnetic resonance imaging gadolinium-enhanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001322-54 Sponsor Protocol Number: CS/2018/6632 Start Date*: 2020-06-15
    Sponsor Name:University Hospitals Bristol and Weston NHS Foundation Trust
    Full Title: Carbon Dioxide Insufflation and Brain Protection During Open Heart Surgery: A Randomised Controlled Trial
    Medical condition: Brain injury during open heart valve surgery
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10067967 Brain injury PT
    21.1 100000004865 10048935 Open heart surgery LLT
    20.0 10029205 - Nervous system disorders 10077808 Mild neurocognitive disorder LLT
    20.0 10047065 - Vascular disorders 10001526 Air embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-005555-27 Sponsor Protocol Number: ESR-14-10473 Start Date*: 2017-09-12
    Sponsor Name:University Hospital Basel
    Full Title: Prevention of Cerebral Ischaemia in Stent Treatment for Carotid Artery Stenosis - A randomised multi-centre phase II trial comparing Ticagrelor versus Clopidogrel with outcome assessment on MRI (PR...
    Medical condition: Carotid artery stenting (CAS) is treatment for atherosclerotic carotid stenosis. The main adverse events are thromboembolic brain infarcts during the procedure. Ticagrelor, a novel reversible inhib...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014724-32 Sponsor Protocol Number: SABA Start Date*: Information not available in EudraCT
    Sponsor Name:University Medical Center Eppendorf
    Full Title: SAFETY, TOLERABILITY AND MECHANISM OF ACTION OF BOSWELLIC ACIDS (BA) IN MULTIPLE SCLEROSIS (MS) AND CLINICALLY ISOLATED SYNDROME (CIS): A MRI-CONTROLLED, MULTICENTER, BASELINE-TO-TREATMENT, 32-WEEK...
    Medical condition: Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003858-24 Sponsor Protocol Number: 252BN201 Start Date*: 2019-08-13
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Double-Blind, Multidose, Placebo-Controlled, Randomized, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 for Patients with Brain Contusion
    Medical condition: Brain contusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10052346 Brain contusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005735-79 Sponsor Protocol Number: UC-BCG-2011 Start Date*: 2021-09-02
    Sponsor Name:UNICANCER
    Full Title: Treatment with Tucatinib in addition to Pertuzumab and Trastuzumab in patients with HER2-positive metastatic breast cancer after local therapy of isolated brain progression
    Medical condition: HER2-positive metastatic breast cancer with isolated brain progression (defined as new or progressive brain metastases with stable or responding systemic disease) after complete local treatment.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:57:21 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA